Frontlight ResearchEarly access
Taking peoplePhase 4
Oral Switch in Bloodstream Infections in Immunocompromised Children
Key facts
- Who runs it
- Copenhagen University Hospital, Rigshospitalet
- Where
- Denmark4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 114 people, planned
- Started
- 9 Nov 2026
- Expected to end
- 1 Feb 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Oral antibiotic therapy
- Standard IV antibiotic therapy
- Record updated
- 10 November 2026
Who can take part
- Age
- 4 weeks to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 4 weeks to 17 years
- Underlying medical condition associated with immunosuppression and/or presence of a central venous catheter
- Positive blood culture with a high-pathogenic bacterium. Eligible pathogens include Gram-negative bacteria and Gram-positive bacteria such as Staphylococcus aureus, Streptococcus mitis, Streptococcus pneumoniae, β-haemolytic streptococci, and Enterococcus spp., for which standard treatment is at least 7 days of intravenous antibiotics
- Clinical stability, defined as: (a) respiratory and hemodynamically stable, without need for oxygen, IV fluid therapy or inotropic support; and (b) well-appearing with signs of clinical improvement (e.g., improved physical activity), as judged by the investigator
- Afebrile for 24 hours
- Tolerating oral fluids and diet and considered to have adequate gastrointestinal absorption for age, as judged by the investigator
- Within the randomization window: i) As soon as possible after eligibility is confirmed and ii) within 3-6 days of effective IV antibiotics (72-144 hours) including the duration of the last IV dose
- Informed consent obtained from a parent or guardian, and from the patient if of appropriate age; Polymicrobial episodes are allowed
Who cannot take part
- Within the follow-up period (≤6 weeks) of a previous randomization for another pathogen covered by the antibiotic indicated for the index episode
- Complicated infections; Tunnel infection associated with a CVC, unless the CVC is removed; Suspected CNS infection; Other focal infections requiring prolonged antibiotic therapy beyond the treatment of bacteremia, e.g., deep-seated abscess or other deep-seated infections, bone or joint infections, and endocarditis
- Planned to receive prophylactic antibiotic therapy covering the pathogen after completion of treatment for the index infection
- Blood culture with Pseudomonas aeruginosa, Neisseria meningitidis, or low-pathogenic possible contaminants of uncertain clinical relevance, including coagulase-negative staphylococci, Micrococcus spp., Corynebacterium spp., Cutibacterium acnes, and Bacillus spp
- Clinically significant mucositis (e.g. stomatitis CTCAE (Common Terminology Criteria for Adverse Events) grade ≥3, defined as severe pain interfering with oral intake)
- No suitable oral antibiotic available (e.g., due to antimicrobial resistance or contraindications)
- A decision to discontinue life-prolonging treatment has been made, with a life expectancy of less than 6 weeks, as assessed by the treating physician
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This nationwide, multicenter, randomized non-inferiority trial aims to determine whether an switch to oral antibiotic therapy (experimental arm) is non-inferior to standard intravenous antibiotic therapy (control arm) with respect to recurrence in children and adolescents with uncomplicated bloodstream infections, who are immunocompromised or have a central venous catheter.
The 2 groups in the trial
- Early Oral SwitchTreatment being tested
Treatment: Oral antibiotic therapy
- Standard Intravenous TherapyExisting treatment, for comparison
Treatment: Standard IV antibiotic therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Oral Switch Versus Standard Intravenous Antibiotics in Children and Adolescents Who Are Immunocompromised and/or a Central Venous Catheter and Uncomplicated Bloodstream Infections: a Nationwide Randomised Controlled Non-inferiority Trial
- Record updated
- 10 November 2026